GlaxoSmithKline Pharmaceuticals Ltd
GlaxoSmithKline Pharmaceuticals's GHG Emissions Data Preview
In 2024, GlaxoSmithKline Pharmaceuticals completed a corporate carbon footprint assessment and publicly disclosed its greenhouse gas (GHG) emissions according to the GHG Protocol, covering Scope 1 (direct emissions from owned or controlled sources), and Scope 2 (indirect emissions from purchased energy).
However, GlaxoSmithKline Pharmaceuticals has not published a category-level breakdown of its Scope 3 emissions, limiting visibility into specific value chain sources.
| Metric (tCO2e) | 2024 | 2023 | 2022 | 2021 - 2017 |
|---|---|---|---|---|
Total Scope 1 | 0000000 | Copy restricted. Please purchase to unlock this data.  | Copy restricted. Please purchase to unlock this data.  | 0000000 |
Total Scope 2 | ||||
Unspecified Calculation Method | 0000000 | Copy restricted. Please purchase to unlock this data.  | Copy restricted. Please purchase to unlock this data. | 0000000 |
Total Scope 3 | 0000000 | Copy restricted. Please purchase to unlock this data. | Copy restricted. Please purchase to unlock this data. | 0000000 |
This table provides a simplified preview of selected GHG emissions data points. To access the complete dataset with full disclosures, detailed breakdowns, and source traceability, create a free account to view purchase options.
Insights into GlaxoSmithKline Pharmaceuticals's Operational Emissions
In 2024, the total operational greenhouse gas (GHG) emissions of GlaxoSmithKline Pharmaceuticals amounted to 10,732.24 metric tons of CO2 equivalent. This figure includes both direct emissions from owned or controlled sources (Scope 1) and indirect emissions from purchased energy (Scope 2).
Compared to 2023, the total operational greenhouse gas (GHG) emissions of GlaxoSmithKline Pharmaceuticals increased by 0.4%, suggesting that the company faced challenges in reducing its emissions from its core operations.
GlaxoSmithKline Pharmaceuticals's Scope 1 Emissions Over Time
- Total Scope 1
- Year-over-Year Change
What are GlaxoSmithKline Pharmaceuticals's Scope 1 emissions?
In 2024, the total Scope 1 emissions of GlaxoSmithKline Pharmaceuticals were 774.32 metric tons of COâ‚‚ equivalent (tCOâ‚‚e).
Compared to the previous year (2023), GlaxoSmithKline Pharmaceuticals's Scope 1 emissions increased by 59.01%, suggesting that the company faced challenges in reducing emissions from its directly owned or controlled operations.
What are GlaxoSmithKline Pharmaceuticals's Scope 2 emissions?
In 2024, GlaxoSmithKline Pharmaceuticals reported Scope 2 greenhouse gas (GHG) emissions of 9,957.92 tCOâ‚‚e without specifying the calculation method.
Has GlaxoSmithKline Pharmaceuticals reduced its Scope 2 emissions over time?
Compared to the previous year (2023), GlaxoSmithKline Pharmaceuticals's Scope 2 emissions (Unspecified Calculation Method) have remained relatively stable, indicating that GlaxoSmithKline Pharmaceuticals 's emissions have plateaued with no significant change in its energy consumption footprint.
What methodology does GlaxoSmithKline Pharmaceuticals use for Scope 2 reporting?
In 2024, GlaxoSmithKline Pharmaceuticals reported its Scope 2 emissions using an unspecified methodology.
GlaxoSmithKline Pharmaceuticals's Scope 2 Emissions Over Time
- Total Scope 2 (Unspecified Calculation Method)